Levetiracetam Reduces Myoclonus in Corticobasal Degeneration: Report of Two Cases

Overview

Journal J Neural Transm (Vienna)

Specialties Neurology
Physiology

Date 2009 Sep 17

PMID 19756367

Citations 7

Authors

Tibor Kovacs

Marianna Farsang

Edina Vitaszil

Peter Barsi

Tamas Gyorke

Imre Szirmai

Anita Kamondi

Affiliations

Soon will be listed here.

Abstract

Levetiracetam (LEV) has been shown to suppress myoclonus of various origins. Corticobasal degeneration (CBD), a progressive neurodegenerative disorder with Parkinsonian syndrome, is frequently accompanied by myoclonus. We investigated the effect of LEV on myoclonus in two CBD patients. LEV remarkably decreased the myoclonic activity in both patients already at 1,500 mg/day dose. This is the first report on LEV alleviating myoclonus in CBD. Our data indicate that it might be worthwhile to assess this effect in an appropriately designed study.

Citing Articles

Myoclonus in older Cavalier King Charles Spaniels.

Rotter C, Whittaker D, Rusbridge C J Vet Intern Med. 2022; 36(3):1032-1038.

PMID: 35319117 PMC: 9151451. DOI: 10.1111/jvim.16404.

Progressive Supranuclear Palsy and Corticobasal Degeneration.

Coughlin D, Dickson D, Josephs K, Litvan I Adv Exp Med Biol. 2021; 1281:151-176.

PMID: 33433875 DOI: 10.1007/978-3-030-51140-1_11.

Pharmacological interventions in corticobasal degeneration: a review.

Caixeta L, Caixeta V, Nogueira Y, Aversi-Ferreira T Dement Neuropsychol. 2020; 14(3):243-247.

PMID: 32973978 PMC: 7500816. DOI: 10.1590/1980-57642020dn14-030006.

Physiology-Based Treatment of Myoclonus.

Pena A, Caviness J Neurotherapeutics. 2020; 17(4):1665-1680.

PMID: 32910414 PMC: 7851206. DOI: 10.1007/s13311-020-00922-6.

An update and review of the treatment of myoclonus.

Mills K, Mari Z Curr Neurol Neurosci Rep. 2014; 15(1):512.

PMID: 25398378 DOI: 10.1007/s11910-014-0512-2.

References

Meco G, Fabrizio E, Epifanio A, Morgante F, Valente M, Vanacore N . Levetiracetam in tardive dyskinesia. Clin Neuropharmacol. 2006; 29(5):265-8. DOI: 10.1097/01.WNF.0000228807.49044.7D. View

Litvan I, Bhatia K, Burn D, Goetz C, Lang A, McKeith I . Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord. 2003; 18(5):467-86. DOI: 10.1002/mds.10459. View

Crest C, Dupont S, Leguern E, Adam C, Baulac M . Levetiracetam in progressive myoclonic epilepsy: an exploratory study in 9 patients. Neurology. 2004; 62(4):640-3. DOI: 10.1212/01.wnl.0000110193.78872.dd. View

Keswani S, Kossoff E, Krauss G, Hagerty C . Amelioration of spinal myoclonus with levetiracetam. J Neurol Neurosurg Psychiatry. 2002; 73(4):457-8. PMC: 1738068. DOI: 10.1136/jnnp.73.4.457. View

Striano P, Manganelli F, Boccella P, Perretti A, Striano S . Levetiracetam in patients with cortical myoclonus: a clinical and electrophysiological study. Mov Disord. 2005; 20(12):1610-4. DOI: 10.1002/mds.20530. View

Sawle G, Brooks D, Marsden C, Frackowiak R . Corticobasal degeneration. A unique pattern of regional cortical oxygen hypometabolism and striatal fluorodopa uptake demonstrated by positron emission tomography. Brain. 1991; 114 ( Pt 1B):541-56. DOI: 10.1093/brain/114.1.541. View

Margineanu D, Klitgaard H . Inhibition of neuronal hypersynchrony in vitro differentiates levetiracetam from classical antiepileptic drugs. Pharmacol Res. 2000; 42(4):281-5. DOI: 10.1006/phrs.2000.0689. View

Krauss G, Bergin A, Kramer R, Cho Y, Reich S . Suppression of post-hypoxic and post-encephalitic myoclonus with levetiracetam. Neurology. 2001; 56(3):411-2. DOI: 10.1212/wnl.56.3.411. View

Agarwal P, Frucht S . Myoclonus. Curr Opin Neurol. 2003; 16(4):515-21. DOI: 10.1097/01.wco.0000084231.82329.9c. View

10.

Lyons K, Pahwa R . Efficacy and tolerability of levetiracetam in Parkinson disease patients with levodopa-induced dyskinesia. Clin Neuropharmacol. 2006; 29(3):148-53. DOI: 10.1097/01.WNF.0000220814.48360.F4. View

11.

Kompoliti K, Goetz C, Boeve B, Maraganore D, Ahlskog J, Marsden C . Clinical presentation and pharmacological therapy in corticobasal degeneration. Arch Neurol. 1998; 55(7):957-61. DOI: 10.1001/archneur.55.7.957. View

12.

Mima T, Nagamine T, Ikeda A, Yazawa S, Kimura J, Shibasaki H . Pathogenesis of cortical myoclonus studied by magnetoencephalography. Ann Neurol. 1998; 43(5):598-607. DOI: 10.1002/ana.410430507. View

13.

Fahn S . Overview, history, and classification of myoclonus. Adv Neurol. 2002; 89:13-7. View

14.

Shibasaki H, Kuroiwa Y . Electroencephalographic correlates of myoclonus. Electroencephalogr Clin Neurophysiol. 1975; 39(5):455-63. DOI: 10.1016/0013-4694(75)90046-2. View

15.

Thompson P, Day B, Rothwell J, Brown P, Britton T, Marsden C . The myoclonus in corticobasal degeneration. Evidence for two forms of cortical reflex myoclonus. Brain. 1994; 117 ( Pt 5):1197-207. DOI: 10.1093/brain/117.5.1197. View

16.

Grosse P, Kuhn A, Cordivari C, Brown P . Coherence analysis in the myoclonus of corticobasal degeneration. Mov Disord. 2003; 18(11):1345-50. DOI: 10.1002/mds.10535. View

17.

Boeve B, Lang A, Litvan I . Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. Ann Neurol. 2003; 54 Suppl 5:S15-9. DOI: 10.1002/ana.10570. View

18.

Zesiewicz T, Louis E, Sullivan K, Menkin M, Dunne P, Hauser R . Substantial improvement in a Meige's syndrome patient with levetiracetam treatment. Mov Disord. 2004; 19(12):1518-21. DOI: 10.1002/mds.20233. View

19.

Lynch B, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh S, Matagne A . The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci U S A. 2004; 101(26):9861-6. PMC: 470764. DOI: 10.1073/pnas.0308208101. View

20.

de Tommaso M, Fruscolo O, Sciruicchio V, Specchio N, Cormio C, De Caro M . Efficacy of levetiracetam in Huntington disease. Clin Neuropharmacol. 2005; 28(6):280-4. View